Cromolyn
Gastrocrom (cromolyn) is a small molecule pharmaceutical. Cromolyn was first approved as Intal on 1982-01-01. It is used to treat allergic rhinitis perennial, asthma, bronchial spasm, conjunctivitis, and food hypersensitivity amongst others in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Gastrocrom (generic drugs available since 1999-06-16, discontinued: Crolom, Cromoptic, Intal, Nasalcrom, Opticrom)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cromolyn sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GASTROCROM | Mylan | N-020479 RX | 1996-02-29 | 1 products, RLD, RS |
Show 6 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cromolyn sodium | ANDA | 2023-06-07 |
| gastrocrom | New Drug Application | 2018-10-10 |
| nasalcrom | ANDA | 2020-08-05 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
| asthma | EFO_0000270 | D001249 | J45 |
| bronchial spasm | — | D001986 | — |
| conjunctivitis | — | D003231 | H10 |
| food hypersensitivity | EFO_1001890 | D005512 | — |
| inflammatory bowel diseases | EFO_0003767 | D015212 | — |
| mastocytosis | — | D008415 | D47.09 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07E: Intestinal antiinflammatory agents
— A07EB: Antiallergic intestinal antiinflammatory drugs, excl. corticosteroids
— A07EB01: Cromoglicic acid
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AH: Agents for dermatitis, excluding corticosteroids
— D11AH03: Cromoglicic acid
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AC: Antiallergic nasal preparations for topical use, excl. corticosteroids
— R01AC01: Cromoglicic acid
— R01AC51: Cromoglicic acid, combinations
— R03: Drugs for obstructive airway diseases
— R03B: Other drugs for obstructive airway diseases, inhalants in atc
— R03BC: Antiallergic inhalants for obstructive airway diseases, excl. corticosteroids
— R03BC01: Cromoglicic acid
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01G: Decongestants and antiallergics
— S01GX: Other antiallergics in atc
— S01GX01: Cromoglicic acid
— S01GX51: Cromoglicic acid, combinations
Clinical
Clinical Trials
424 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 11 | 20 | 8 | 2 | 2 | 39 | |
| Septic shock | D012772 | A48.3 | 1 | 7 | 12 | 5 | 4 | 26 | |
| Adrenal insufficiency | D000309 | 4 | 3 | 3 | 8 | 3 | 20 | ||
| Sepsis | D018805 | A41.9 | — | 4 | 6 | 3 | 7 | 19 | |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | 6 | — | 5 | 3 | 15 |
| Congenital adrenal hyperplasia | D000312 | E25.0 | 4 | 7 | 2 | 3 | 1 | 15 | |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | 3 | 9 | 13 |
| Healthy volunteers/patients | — | 5 | 1 | 1 | 2 | — | 9 | ||
| Addison disease | D000224 | E27.1 | 1 | 5 | 1 | 1 | 3 | 9 | |
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | 2 | 3 | 1 | — | 7 |
Show 39 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | 1 | 12 | 10 | — | 2 | 24 | |
| Prostatic neoplasms | D011471 | C61 | 2 | 11 | 5 | — | 1 | 17 | |
| Lymphoma | D008223 | C85.9 | — | 6 | 6 | — | — | 12 | |
| Myeloid leukemia acute | D015470 | C92.0 | 6 | 3 | 2 | — | — | 10 | |
| Myelodysplastic syndromes | D009190 | D46 | 3 | — | 3 | — | — | 6 | |
| Heart arrest | D006323 | EFO_0009492 | I46 | 2 | 2 | 2 | — | 2 | 6 |
| Covid-19 | D000086382 | U07.1 | — | — | 2 | — | 3 | 5 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 3 | — | 1 | 4 |
| Bronchopulmonary dysplasia | D001997 | P27.8 | — | 2 | 2 | — | — | 4 | |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | 1 | 1 | — | 1 | 3 |
Show 35 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 2 | 1 | — | — | 2 | 5 |
| Hemorrhoids | D006484 | EFO_0009552 | K64 | — | 3 | — | — | 1 | 4 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | 2 | — | — | 1 | 3 |
| Neoplasms | D009369 | C80 | — | 3 | — | — | — | 3 | |
| Burkitt lymphoma | D002051 | C83.7 | 1 | 3 | — | — | — | 3 | |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 3 | — | — | — | 3 |
| Biphenotypic leukemia acute | D015456 | C95.0 | — | 2 | — | — | — | 2 | |
| Head and neck neoplasms | D006258 | — | 1 | — | — | 1 | 2 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 1 | 2 |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 1 | 2 | — | — | — | 2 |
Show 44 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 4 | — | — | — | 2 | 6 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 2 | — | — | — | — | 2 |
| Hematologic neoplasms | D019337 | 1 | — | — | — | 1 | 2 | ||
| Blood pressure | D001794 | EFO_0004325 | 2 | — | — | — | — | 2 | |
| T-cell lymphoma | D016399 | 2 | — | — | — | — | 2 | ||
| Insulin resistance | D007333 | EFO_0002614 | 1 | — | — | — | 1 | 2 | |
| Cocaine-related disorders | D019970 | F14 | 1 | — | — | — | 1 | 2 | |
| Infections | D007239 | EFO_0000544 | 1 | — | — | — | 1 | 2 | |
| Recurrence | D012008 | 2 | — | — | — | — | 2 | ||
| T-cell lymphoma peripheral | D016411 | C84.9 | 1 | — | — | — | — | 1 |
Show 23 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | — | 3 | 3 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | — | 2 | 2 |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | — | 2 | 2 | |
| Plantar fasciitis | D036981 | EFO_1001909 | M72.2 | — | — | — | — | 1 | 1 |
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | — | — | — | 1 | 1 |
| Deglutition disorders | D003680 | HP_0002015 | R13.1 | — | — | — | — | 1 | 1 |
| Thyroidectomy | D013965 | — | — | — | — | 1 | 1 | ||
| Pituitary diseases | D010900 | E23.7 | — | — | — | — | 1 | 1 | |
| Circadian rhythm sleep disorders | D020178 | G47.2 | — | — | — | — | 1 | 1 | |
| Hypopituitarism | D007018 | EFO_0001380 | E23.0 | — | — | — | — | 1 | 1 |
Show 48 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CROMOLYN |
| INN | cromoglicic acid |
| Description | Cromoglycic acid is a dicarboxylic acid that is the bis-chromone derivative of glycerol. It is effective as a mast cell stabilizer. It has a role as a calcium channel blocker and an anti-asthmatic drug. It is a dicarboxylic acid and a member of chromones. It is a conjugate acid of a cromoglycate(1-). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1 |
Identifiers
| PDB | — |
| CAS-ID | 16110-51-3 |
| RxCUI | 42612 |
| ChEMBL ID | CHEMBL428880 |
| ChEBI ID | 59773 |
| PubChem CID | 2882 |
| DrugBank | DB01003 |
| UNII ID | Y0TK0FS77W (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,513 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,226 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more